Improving transplant quality of care often begins with examining practice outcomes. We follow patients from candidacy evaluation through listing, transplant hospitalization, and on to the very end. The volume of items tracked is monumental-rejection, graft failure, viral infections, organ function, bone density, cardiac function, length of stay, immunosuppressant regimen, and a myriad of others; all by organ transplanted, by race, by gender, by pretransplant status, by type of organ procured, and however many ways we can think of to split the data. There is so much information to mine. You never think about this data belonging to anyone but you, as you have lived with this information for so long that it begins to feel like it is a part of you. Why wouldn't a patient trust you to use his/her biomedical information wisely?
Did that trust include publication of center-specific data? You may immediately say of course, what harm was provided to this patient by including their biomedical data in a report of center outcomes? Since the introduction of the Health Insurance Portability and Accountability Act of 1996 in the United States along with subsequent modifications, 1 we have all had to rethink how a patient's biomedical information was entrusted to us. Later revisions of this legislation outlined protection of health information specifically for research purposes. The European Union readdressed this issue with the European General Data Protection Regulation 2 of 2012 that outlined specific consents to the use of personal data.
This effects authors in what way? Evaluating your own program is crucial and will continue to be an important activity to improve care, but when sharing your accomplishments in presentations and publications, you enter the realm of publication ethics. Can you publish your findings? This is where you need to ask the question: Have you received specific consent from patients to use any or all of their biomedical information beyond program evaluation?
When considering publication, authors must be cognizant of consenting issues and data source transparency. We return to the trust between you as the representative of the transplant center and your patients, as patients have a choice on what data can be shared beyond immediate medical care decisions. Each author needs to describe how permission to use biomedical information was obtained. How you disseminate program evaluation is within your ethical role as a clinician or an investigator who wish to publish findings.
Investigators often do this in several ways. One way is to create an all-encompassing consent at the time of referral to the transplant center (although this use becomes ethically tricky), requesting permission to use data if the group is small, or by developing a research plan with individual consents for patients. Authors must share how the biomedical data submitted for publication were protected according to general laws as well as by the institutional review process. The editor's role is to publish science articles that are conducted by the highest standards and without authors explicating this process, it is impossible to insure patient data confidentiality. 3 Before you mine your center's medical records, know what data were consented for you to use in publication and dissemination. Honor the trust. 
